Cancer antibodies, proteins, and reagents for cancer research

Melanoma research

Antibodies for the analysis of melanoma onset and development

SnapShot from Cell Press: Melanoma poster

View or download PDF

The “SnapShot from Cell Press: Melanoma” poster describes the most common mutations resulting in melanomas and disease progression as well as cell signaling cascades frequently altered in this disease. These include the PI3-Kinase/AKT and the MAPK/ERK mediated signaling pathways. Aberrant regulation of the latter is most commonly triggered by constitutive BRAF kinase activity caused by a mutation of valine residue 600 to glutamic acid (BRAF (V600E)). Other regular triggers of melanoma development include mutations in the NRAS proto-oncogene and the TP53, PTEN tumor suppressor genes. Mutations in CD117/KIT have also been reported, although at a much lower frequency. For a complete overview of the frequency of the common mutations and deletions resulting in melanoma, download or request the melanoma poster.

In order to make it easier for you to select reagents for melanoma research, we have grouped antibodies against the critical proteins mentioned on the poster together in a convenient selector tool. These include our range of p53 antibodies, mTOR and MEK1 PrecisionAb™ Western blot validated antibodies. Each PrecisionAb product has been carefully selected after comprehensive performance testing in up to twelve different whole cell lysates. PrecisionAb products are characterized by their high specificity, high sensitivity and batch to batch consistency (every antibody lot has to meet the same strict quality control criteria). For more information, check our PrecisionAb range.


Antibodies for Melanoma Research

Melanoma

AKT1
BAX
Cdk4
ERK1
mTOR
PI-3 Kinase
TRAF2
AKT2
BIM
CYCLIN D1
H-Ras
NFkB
PTEN
WT1
ARAF
CATENIN BETA
EGF R
MDM2
p21/WAF1
RAC2
BAD
CD117/KIT
ERK/MAPK
MEK 1
p53
RAF-1

Antibodies for Melanoma

    DescriptionSpecificityTargetFormatHostIsotypeClone Applications Citations Product Type Code